Literature DB >> 32127140

The regression of endometriosis with glycosylated flavonoids isolated from Melilotus officinalis (L.) Pall. in an endometriosis rat model.

Mert Ilhan1, Zulfiqar Ali2, Ikhlas A Khan2, Hakkı Taştan3, Esra Küpeli Akkol4.   

Abstract

OBJECTIVE: Melilotus officinalis (L.) Pall. is commonly used for treating bronchitis, painful menstruation, hemorrhoids, kidney stones, ulcers of the eyes, earache, and hardening and swelling of uterus. The European Medicines Agency reported the use of M. officinalis orally against stomach ache, gastric ulcer, and disorders of the liver and uterus in folk medicine. The present study aimed to appraise the activity of M. (L.) Pall. aerial parts in endometriosis rat model.
MATERIALS AND METHODS: The endometriosis rat model was used to evaluate the potential activity of M. officinalis aerial parts based on its folkloric usage. The aerial parts of M. officinalis were extracted with n-hexane, ethyl acetate (EtOAc), and methanol (MeOH), respectively. The adhesion scores, endometrial foci areas, and cytokine levels were measured in all treated groups. After the biological activity studies, phytochemical studies were performed on the active extract and the fractions obtained from the active extract.
RESULTS: The MeOH extract significantly decreased the endometrial foci areas and cytokine levels in rats with endometriosis. Fractionation was performed on the MeOH extract to achieve bioactive molecules. Following the fractionation, the fractions obtained from the MeOH extract were tested. Fraction C showed the highest activity in the rat endometriosis model. Phytochemical investigation of the active fraction (Fraction C) resulted in isolation and elucidation of some quercetin and kaempferol glucoside derivatives.
CONCLUSION: Fraction C obtained from the MeOH extract of M. officinalis showed the highest activity, yielding four glycosylated flavonoids.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Endometriosis; Fabaceae; Glycosylated flavonoids; Melilotus officinalis; Rat

Mesh:

Substances:

Year:  2020        PMID: 32127140     DOI: 10.1016/j.tjog.2020.01.008

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  6 in total

1.  Exploring the Potential Mechanisms of Melilotus officinalis (L.) Pall. in Chronic Muscle Repair Patterns Using Single Cell Receptor-Ligand Marker Analysis and Molecular Dynamics Simulations.

Authors:  Yisheng Chen; Zhiwen Luo; Jinrong Lin; Beijie Qi; Yaying Sun; Fangqi Li; Chenyang Guo; Weiwei Lin; Xueran Kang; Xinyi He; Qian Wang; Shiyi Chen; Jiwu Chen
Journal:  Dis Markers       Date:  2022-06-01       Impact factor: 3.464

Review 2.  Flavonoids: structure-function and mechanisms of action and opportunities for drug development.

Authors:  Stephen Safe; Arul Jayaraman; Robert S Chapkin; Marcell Howard; Kumaravel Mohankumar; Rupesh Shrestha
Journal:  Toxicol Res       Date:  2021-01-20

3.  Utilizing network pharmacology and molecular docking to explore the underlying mechanism of Guizhi Fuling Wan in treating endometriosis.

Authors:  Haoxian Wang; Gang Zhou; Mingyan Zhuang; Wei Wang; Xianyun Fu
Journal:  PeerJ       Date:  2021-04-02       Impact factor: 2.984

4.  Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis.

Authors:  Haoxian Wang; Jihong Zhang; Qinqin Zhu; Xianyun Fu; Chenjie Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-26       Impact factor: 2.629

Review 5.  Ameliorating Effects of Natural Antioxidant Compounds on Female Infertility: a Review.

Authors:  Jitender Kumar Bhardwaj; Harish Panchal; Priyanka Saraf
Journal:  Reprod Sci       Date:  2020-09-15       Impact factor: 3.060

6.  Network Pharmacology-Based Prediction of Bioactive Compounds and Potential Targets of Wenjing Decoction for Treatment of Endometriosis.

Authors:  Yu-Nan Liu; Xiao-Jing Hu; Bei Liu; Yu-Jie Shang; Wen-Ting Xu; Hui-Fang Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-24       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.